Zantrene AML trial in Israel advances to Phase 2
Filed with ASX · · 6 pages · English
Earlier from Racura Oncology
- Race Receives Governance Approval for AML EMD & MDS Trial
- Race receives Human Ethics AML Trial Approval
- Supply Agreement for EMD AML Trial
- Zantrene highly effective in EMD AML Mouse Model
- Race Oncology: ASX Small and Mid-Cap Conference Presentation
Later from Racura Oncology
- EMD AML MDS Trial Expands to Europe
- Race Oncology Announces On-Market Share Buyback
- Zantrene Improves Immune Therapy Treatment of Melanoma
- Zantrene shows synergy with kinase inhibitors in melanoma
- Zantrene Protects Mouse Hearts from Chemotherapy Damage
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology